Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Mazdutide Study: Phase 3 Trial vs Tirzepatide and Semaglutide Comparison

Mean Weight Loss (48–72 weeks) 20.6% at 48 weeks 20.9% at 72 weeks 14.9% at 68 weeks Mazdutide achieves tirzepatide-level efficacy in two-thirds the time. Suggesting faster onset kinetics HbA1c Reduction (prediabetes/T2D subgroup) −1.1% at 48 weeks −0.94% at 7

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Mean Weight Loss (48–72 weeks)
  • 20.6% at 48 weeks
  • 20.9% at 72 weeks
  • 14.9% at 68 weeks
  • Mazdutide achieves tirzepatide-level efficacy in two-thirds the time. Suggesting faster onset kinetics
  • HbA1c Reduction (prediabetes/T2D subgroup)
  • −1.1% at 48 weeks
  • −0.94% at 72 weeks
  • −0.78% at 68 weeks
  • Mazdutide's glucagon component appears to drive greater insulin sensitivity improvements per kilogram of weight lost
  • Gastrointestinal Adverse Events
  • 38% (nausea, vomiting, diarrhea)
  • 42% (nausea, vomiting, diarrhea)
  • 44% (nausea, vomiting, diarrhea)
  • Lower GI event rate suggests dose titration schedule may be better optimized than competitors
  • REE Increase vs Baseline
  • +15% at 24 weeks
  • +4% at 24 weeks
  • +2% at 24 weeks
  • Only mazdutide produces clinically significant metabolic rate elevation. The glucagon component's clearest differentiator
  • Discontinuation Rate (all-cause)
  • 12% through 48 weeks
  • 14% through 72 weeks
  • 17% through 68 weeks
  • Lower dropout rate likely reflects shorter trial duration rather than superior tolerability
  • Regulatory Status (2026)
  • Phase 3 complete, FDA submission expected Q2 2026
  • FDA-approved 2023
  • FDA-approved 2021
  • Mazdutide remains investigational. Earliest approval timeline is late 2026 or early 2027
  • The mazdutide study demonstrates weight loss magnitude comparable to tirzepatide but with a metabolic profile distinct from either tirzepatide or semaglutide. Specifically, the thermogenic effect measured as resting energy expenditure increase. Pure GLP-1 agonists produce modest REE increases (2–4%) attributable to the thermic effect of food and minor sympathetic activation. Mazdutide's 15% REE elevation at 24 weeks suggests glucagon receptor activation drives mitochondrial uncoupling in brown adipose tissue and hepatic thermogenesis. Mechanisms that operate independently of caloric restriction.